Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.

Fiche publication

Date publication

janvier 2025

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NERICH Virginie , Mr FALCOZ Antoine , Mme MEURISSE Aurélia

Tous les auteurs :
Nerich V, Falcoz A, Nadin L, Meurisse A, Pechery A, Bourhis J, Sun XS, Thariat J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39837424

Résumé

The randomized phase II GORTEC 2014-04 and French Head and Neck Intergroup study showed deeper deterioration of the quality of life (HRQoL) and dramatically higher severe toxicity rates with similar overall survival rates using chemo-SABR compared to SABR alone in oligometastatic head and neck cancer (HNSCC) patients. We evaluated the costs associated with SABR-alone versus chemo-SABR and their associated costs (transportation, hospitalizations, etc).